Vonoprazan: MarKed Competition for PPIs?

Dig Dis Sci. 2016 Jul;61(7):1783-4. doi: 10.1007/s10620-016-4164-8.

Authors

David R Scott^{1

2}, Elizabeth A Marcus^{3

4}, George Sachs^{5

6

4}

Affiliations

¹ Department of Physiology, DGSOM at UCLA, Los Angeles, CA, USA. dscott@ucla.edu.
² VA GLAHS, 11301 Wilshire Blvd., Bldg. 113, Rm. 324, Los Angeles, CA, USA. dscott@ucla.edu.
³ Department of Pediatrics, DGSOM at UCLA, Los Angeles, CA, USA.
⁴ VA GLAHS, 11301 Wilshire Blvd., Bldg. 113, Rm. 324, Los Angeles, CA, USA.
⁵ Department of Physiology, DGSOM at UCLA, Los Angeles, CA, USA.
⁶ Department of Medicine, DGSOM at UCLA, Los Angeles, CA, USA.

No abstract available

Publication types

Editorial
Comment

MeSH terms

Humans
Proton Pump Inhibitors*
Pyrroles
Sulfonamides*

Substances

1-(5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl)-N-methylmethanamine
Proton Pump Inhibitors
Pyrroles
Sulfonamides

Grants and funding